Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lifecore’s Withdrawn Intergel Solution Represented 12% Of 2002 Revenues

This article was originally published in The Gray Sheet

Executive Summary

Lifecore Biomedical and Johnson & Johnson/Ethicon will investigate adverse events involving the firm's Intergel adhesion prevention solution following a voluntary market withdrawal of the device by J&J March 27
Advertisement

Related Content

Lifecore Biomedical Warning Letter Spotlights Intergel Adverse Event Issues
Lifecore Biomedical Warning Letter Spotlights Intergel Adverse Event Issues
Lifecore Biomedical CEO Resigns; Intergel Withdrawal Review Continues
Lifecore Biomedical CEO Resigns; Intergel Withdrawal Review Continues
Pediatric Study Required To Monitor Repel-CV Cardiac Adhesion Barrier
Pediatric Study Required To Monitor Repel-CV Cardiac Adhesion Barrier
Staar Surgical Shares Up 62% As Investors Glimpse ICL Clinical Data
Staar Surgical Shares Up 62% As Investors Glimpse ICL Clinical Data
Advertisement
UsernamePublicRestriction

Register

MT018125

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel